Latest: FDA Approves New Biosimilar for Oncology Treatment

Soluble CD83 Levels Reduced in NMOSD and Relapsing MOGAD, Pointing to Potential Biomarker

by Neurology Live

13 September, 2025

0 Mins

New findings highlight the potential of sCD83 as a prognostic biomarker in NMOSD and MOGAD, supporting its role as both a therapeutic target and a marker of treatment response in these autoimmune diseases.

Tags:

Author

Neurology Live

SetPoint Medical Raises $140M to Support Commercialization of Rheumatoid Arthritis Therapy

Policy Tracker: Youth Access to Gender Affirming Care and State Policy Restrictions

📢

300x250 Banner

Soluble CD83 Levels Reduced in NMOSD and Relapsing MOGAD, Pointing to Potential Biomarker

Tags:

Neurology Live

SetPoint Medical Raises $140M to Support Commercialization of Rheumatoid Arthritis Therapy

Policy Tracker: Youth Access to Gender Affirming Care and State Policy Restrictions

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition